RT Journal Article
SR Electronic
T1 Exome sequencing identifies novel AD-associated genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20159251
DO 10.1101/2020.07.22.20159251
A1 Henne Holstege
A1 Marc Hulsman
A1 Camille Charbonnier
A1 Benjamin Grenier-Boley
A1 Olivier Quenez
A1 Detelina Grozeva
A1 Jeroen G.J. van Rooij
A1 Rebecca Sims
A1 Shahzad Ahmad
A1 Najaf Amin
A1 Penny J. Norsworthy
A1 Oriol Dols-Icardo
A1 Holger Hummerich
A1 Amit Kawalia
A1 Philippe Amouyel
A1 Gary W. Beecham
A1 Claudine Berr
A1 Joshua C. Bis
A1 Anne Boland
A1 Paola Bossù
A1 Femke Bouwman
A1 Dominique Campion
A1 Antonio Daniele
A1 Jean-François Dartigues
A1 Stéphanie Debette
A1 Jean-François Deleuze
A1 Nicola Denning
A1 Anita L DeStefano
A1 Lindsay A. Farrer
A1 Nick C. Fox
A1 Daniela Galimberti
A1 Emmanuelle Genin
A1 Jonathan L. Haines
A1 Clive Holmes
A1 M. Arfan Ikram
A1 M. Kamran Ikram
A1 Iris Jansen
A1 Robert Kraaij
A1 Marc Lathrop
A1 Evelien Lemstra
A1 Alberto Lleó
A1 Lauren Luckcuck
A1 Rachel Marshall
A1 Eden R Martin
A1 Carlo Masullo
A1 Richard Mayeux
A1 Patrizia Mecocci
A1 Alun Meggy
A1 Merel O. Mol
A1 Kevin Morgan
A1 Benedetta Nacmia
A1 Adam C Naj
A1 Pau Pastor
A1 Margaret A. Pericak-Vance
A1 Rachel Raybould
A1 Richard Redon
A1 Anne-Claire Richard
A1 Steffi G Riedel-Heller
A1 Fernando Rivadeneira
A1 Stéphane Rousseau
A1 Natalie S. Ryan
A1 Salha Saad
A1 Pascual Sanchez-Juan
A1 Gerard D. Schellenberg
A1 Philip Scheltens
A1 Jonathan M. Schott
A1 Davide Seripa
A1 Gianfranco Spalleta
A1 Betty Tijms
A1 André G Uitterlinden
A1 Sven J. van der Lee
A1 Michael Wagner
A1 David Wallon
A1 Li-San Wang
A1 Aline Zarea
A1 Marcel J.T. Reinders
A1 Jordi Clarimon
A1 John C. van Swieten
A1 John J. Hardy
A1 Alfredo Ramirez
A1 Simon Mead
A1 Wiesje M. van der Flier
A1 Cornelia M van Duijn
A1 Julie Williams
A1 Gaël Nicolas
A1 Céline Bellenguez
A1 Jean-Charles Lambert
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.22.20159251.abstract
AB Background With the development of next-generation sequencing technologies, it is possible to identify rare genetic variants that influence the risk of complex disorders. To date, whole exome sequencing (WES) strategies have shown that specific clusters of damaging rare variants in the TREM2, SORL1 and ABCA7 genes are associated with an increased risk of developing Alzheimer’s Disease (AD), reaching odds ratios comparable with the APOE-ε4 allele, the main common AD genetic risk factor. Here, we set out to identify additional AD-associated genes by an exome-wide investigation of the burden of rare damaging variants in the genomes of AD cases and cognitively healthy controls.Method We integrated the data from 25,982 samples from the European ADES consortium and the American ADSP consortium. We developed new techniques to homogenize and analyze these data. Carriers of pathogenic variants in genes associated with Mendelian inheritance of dementia were excluded. After quality control, we used 12,652 AD cases and 8,693 controls for analysis. Genes were analyzed using a burden analysis, including both non-synonymous and loss-of-function rare variants, the impact of which was prioritized using REVEL.Result We confirmed that carrying rare protein-damaging genetic variants in TREM2, SORL1 or ABCA7 is associated with increased AD-risk. Moreover, we found that carrying rare damaging variants in the microglial ATP8B4 gene was significantly associated with AD, and we found suggestive evidence that rare variants in ADAM10, ABCA1, ORC6, B3GNT4 and SRC genes associated with increased AD risk. High-impact variants in these genes were mostly extremely rare and enriched in AD patients with earlier ages at onset. Additionally, we identified two suggestive protective associations in CBX3 and PRSS3. We are currently replicating these associations in independent datasets.Conclusion With our newly developed homogenization methods, we identified novel genetic determinants of AD which provide further evidence for a pivotal role of APP processing, lipid metabolism, and microglia and neuroinflammatory processes in AD pathophysiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementACKNOWLEDGMENTS Study participants and personnel involved in sample collection The authors are grateful to the study participants, their family members, and the participating general practitioners, pharmacists and all laboratory personnel involved in blood collection, DNA isolation, and DNA biobanking. CARTESIUS SUPERCOMPUTER The work in this manuscript was carried out on the Cartesius supercomputer, which is embedded in the Dutch national e-infrastructure with the support of SURF Cooperative. Computing hours were granted in 2016, 2017, 2018 and 2019 to H. Holstege by the Dutch Research Council (project name: 100plus; project numbers 15318 and 17232). ADES-FR This study was funded by grants from the Clinical Research Hospital Program from the French Ministry of Health (GMAJ, PHRC, 2008/067), the CNR-MAJ, the JPND PERADES, and Equipe FRM DEQ20170336711. This research was supported by the Laboratory of Excellence GENMED (Medical Genomics) grant no. ANR-10-LABX-0013 managed by the National Research Agency (ANR) part of the Investment for the Future program. This work was also supported by Foundation Alzheimer, the Institut Pasteur de Lille, Inserm, the Haut-de-France and Lille Metropole Communaute Urbaine council, and the French governments LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimers disease). The 3C Study supports are listed on the Study Website (www.three-city-study.com). AgeCoDe-UKBonn The AgeCoDe cohort was funded in part by the German Federal Ministry of Education and Research (BMBF) (grants KNDD 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716, 01ET1006B). Sequencing of AgeCoDe sample was in part funded by the German Research Foundation (DFG) grant RA 1971/6-1 to Alfredo Ramirez. Barcelona-SPIN Support for Jordi Clarimon provided by Maraton RTVE (Spain).Support for Oriol Dols provided by the Association for Frontotemporal Degeneration (Clinical Research Postdoctoral Fellowship, AFTD). 100-plus Study Cohort collection and exome sequencing of the 100-plus Study cohort was supported by Stichting Alzheimer Nederland (WE.09-2014-03); Stichting Dioraphte; JPND-PERADES (ZonMw 733051022): HorstingStuit Foundation, VUmc Fund, and Dioraphte Project 17020403, ERF The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community s Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). Rotterdam Study The generation and management of the exome sequencing data for the Rotterdam Study was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Netherlands. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE) (014-93-015; RIDE2), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the municipality of Rotterdam. Genetic data sets are also supported by the Netherlands Organization of Scientific Research NWO Investments (175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, and the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO), the Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810, and by a Complementation Project of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL; www.bbmri.nl; project number CP2010-41). We thank Mr. Pascal Arp, Ms. Mila Jhamai, Mr. and Marijn Verkerk, for their help in creating the RS-Exome Sequencing database. AC-EMC Exome sequencing was funded by Alzheimer Nederland. ADC-Amsterdam We thank all study participants and all personnel involved in data collection for the contributing studies. Research of Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The chair of Wiesje van der Flier is supported by the Pasman stichting. The clinical database structure was developed with funding from Stichting Dioraphte. This work was supported by Stichting Alzheimer Nederland (WE.09-2014-06, WE.05-2010-06); Stichting Dioraphte; Internationale Stichting Alzheimer Onderzoek (#11519); JPND-PERADES (ZonMw 733051022): Centralized Facility for Sequence to Phenotype analyses (ZonMW 9111025); Netherlands Consortium for Healthy Aging (NCHA 050-060-810); Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL CP2010-41); Netherlands Genomics Initiative (NGI)/NWO. PERADES: We thank all individuals who participated in the study. We also want to express our gratitude to the MRC Centre Core Team for the laboratory support and the Advanced Research Computing at Cardiff University (ARCCA) for the computational support. Cardiff University was supported by the Medical Research Council. Cardiff University was also supported by the European Joint Programme for Neurodegenerative Disease, Alzheimers Research UK, the Welsh Assembly Government, and a donation from the Moondance Charitable Foundation. Cardiff University acknowledges the support of the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer s Society and Alzheimers Research UK. Cambridge University acknowledges support from the MRC. The University of Southampton acknowledges support from the Alzheimers Society. ARUK provided support to Nottingham University. Join Dementia Research (JDR) is funded by the Department of Health and delivered by the National Institute for Health Research in partnership with Alzheimer Scotland, Alzheimers Research UK and Alzheimers Society CBC: Control Brain Consortium This work was supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimers Society and Alzheimers Research UK, Medical Research Council (award number MR/N026004/1). Wellcome Trust Hardy (award number 202903/Z/16/Z), Dolby Family Fund; National Institute for Health Research University College London Hospitals Biomedical Research Centre; BRCNIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London. UCL-DRC EOAD This work was supported by the Medical Research Council (UK), the Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and charitable donations to the UCL Dementia Research Centre. ADSP The Alzheimers Disease Sequencing Project (ADSP) is comprised of two Alzheimers Disease (AD) genetics consortia and three National Human Genome Research Institute (NHGRI) funded Large Scale Sequencing and Analysis Centers (LSAC). The two AD genetics consortia are the Alzheimers Disease Genetics Consortium (ADGC) funded by NIA (U01 AG032984), and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), the National Heart, Lung, and Blood Institute (NHLBI), other National Institute of Health (NIH) institutes and other foreign governmental and non-governmental organizations. The Discovery Phase analysis of sequence data is supported through UF1AG047133 (to Drs. Schellenberg, Farrer, Pericak-Vance, Mayeux, and Haines); U01AG049505 to Dr. Seshadri; U01AG049506 to Dr. Boerwinkle; U01AG049507 to Dr. Wijsman; and U01AG049508 to Dr. Goate and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Goate, U01AG052410 to Dr. Pericak-Vance and U01 AG052409 to Drs. Seshadri and Fornage, U54 AG052427 to Drs. Schellenberg and Wang, and R01 AG054060 to Dr Naj. The ADGC cohorts include: Adult Changes in Thought (ACT) (UO1 AG006781, UO1 HG004610, UO1 HG006375, U01 HG008657), the Alzheimers Disease Centers (ADC) (P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG047366, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681, and P50 AG047270), the Chicago Health and Aging Project (CHAP) (R01 AG11101, RC4 AG039085, K23 AG030944), Indianapolis Ibadan (R01 AG009956, P30 AG010133), the Memory and Aging Project (MAP) ( R01 AG17917), Mayo Clinic (MAYO) (R01 AG032990, U01 AG046139, R01 NS080820, RF1 AG051504, P50 AG016574), Mayo Parkinsons Disease controls (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 AG027944, R01 AG028786, R01 AG019085, IIRG09133827, A2011048), the Multi-Institutional Research in Alzheimers Genetic Epidemiology Study (MIRAGE) (R01 AG09029, R01 AG025259), the National Cell Repository for Alzheimers Disease (NCRAD) (U24 AG21886), the National Institute on Aging Late Onset Alzheimers Disease Family Study (NIA-LOAD) (R01 AG041797), the Religious Orders Study (ROS) (P30 AG10161, R01 AG15819), the Texas Alzheimers Research and Care Consortium (TARCC) (funded by the Darrell K Royal Texas Alzheimers Initiative), Vanderbilt University/Case Western Reserve University (VAN/CWRU) (R01 AG019757, R01 AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimers Association), the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1 AG054023), the University of Washington Families (VA Research Merit Grant, NIA: P50AG005136, R01AG041797, NINDS: R01NS069719), the Columbia University HispanicEstudio Familiar de Influencia Genetica de Alzheimer (EFIGA) (RF1 AG015473), the University of Toronto (UT) (funded by Wellcome Trust, Medical Research Council, Canadian Institutes of Health Research), and Genetic Differences (GD) (R01 AG007584). The CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute (NHLBI) infrastructure grant HL105756 (Psaty), RC2HL102419 (Boerwinkle) and the neurology working group is supported by the National Institute on Aging (NIA) R01 grant AG033193. R01 AG048927 for the Gwangju Alzheimer and Related Dementias Study, RF1 AG054080 to Dr. Beechem, U24 AG056270 to Dr. Mayeux, RF1 AG057519 to Dr. Farrer and Pericak-Vance, U01 AG062602 to Dr. Farrer, R01 AG067501 to Dr. Mayeux, and P30 AG13846 to Dr. Farrer The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke Prevention Study (ASPS), ASPS-Family study, and the Prospective Dementia Registry-Austria (ASPS/PRODEM-Aus), the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and the Medical University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project I904),the EU Joint Programme - Neurodegenerative Disease Research (JPND) in frame of the BRIDGET project (Austria, Ministry of Science) and the Medical University of Graz and the Steiermarkische Krankenanstalten Gesellschaft. PRODEM-Austria is supported by the Austrian Research Promotion agency (FFG) (Project No. 827462) and by the Austrian National Bank (Anniversary Fund, project 15435. ARIC research is carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data in ARIC is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the NHLBI with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629, R01AG15928, and R01AG20098 from the NIA. FHS research is supported by NHLBI contracts N01-HC-25195 and HHSN268201500001I. This study was also supported by additional grants from the NIA (R01s AG054076, AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community s Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the municipality of Rotterdam. Genetic data sets are also supported by the Netherlands Organization of Scientific Research NWO Investments (175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810. All studies are grateful to their participants, faculty and staff. The content of these manuscripts is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the U.S. Department of Health and Human Services. The four LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54 HG003273), the Broad Institute Genome Center (U54HG003067), The American Genome Center at the Uniformed Services University of the Health Sciences (U01AG057659), and the Washington University Genome Institute (U54HG003079). Biological samples and associated phenotypic data used in primary data analyses were stored at Study Investigators institutions, and at the National Cell Repository for Alzheimers Disease (NCRAD, U24AG021886) at Indiana University funded by NIA. Associated Phenotypic Data used in primary and secondary data analyses were provided by Study Investigators, the NIA funded Alzheimers Disease Centers (ADCs), and the National Alzheimers Coordinating Center (NACC, U01AG016976) and the National Institute on Aging Genetics of Alzheimers Disease Data Storage Site (NIAGADS, U24AG041689) at the University of Pennsylvania, funded by NIA This research was supported in part by the Intramural Research Program of the National Institutes of health, National Library of Medicine. Contributors to the Genetic Analysis Data included Study Investigators on projects that were individually funded by NIA, and other NIH institutes, and by private U.S. organizations, or foreign governmental or nongovernmental organizations. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB body from the institutes of all respective studies that contributed to this sample have approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon request.